Entrada Therapeutics (TRDA) grants RSUs and options as automatic share sales cover taxes
Rhea-AI Filing Summary
Entrada Therapeutics, Inc. reported that President of Research & Development Sethuraman Natarajan received new equity awards and had shares disposed to cover tax obligations. On March 1, 2026, he was granted 55,800 restricted stock units (RSUs), each representing one share of common stock, scheduled to vest 25% each on March 1, 2027, March 1, 2028, March 1, 2029, and March 1, 2030, contingent on continued service. He also received a stock option for 83,200 shares of common stock, with 25% vesting on March 1, 2027 and the remaining 75% vesting in 36 equal monthly installments through March 1, 2030. To satisfy minimum statutory tax withholding obligations, the company automatically sold shares on his behalf: 3,898 shares of common stock on March 2, 2026 at a weighted average price of $11.6579 (across trades from $11.17 to $11.91) and 7,577 shares on March 3, 2026 at a weighted average price of $11.7564 (across trades from $11.22 to $12.095). After these transactions, he directly owned 242,224 shares of Entrada’s common stock.
Positive
- None.
Negative
- None.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Tax Withholding | Common Stock | 7,577 | $11.7564 | $89K |
| Tax Withholding | Common Stock | 3,898 | $11.6579 | $45K |
| Grant/Award | Stock Option (Right to Buy) | 83,200 | $0.00 | -- |
| Grant/Award | Common Stock | 55,800 | $0.00 | -- |
Footnotes (1)
- Represents a grant of restricted stock units ("RSUs") under the Issuer's 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one share of the Issuer's common stock. The RSUs shall vest as follows: (i) 25% on March 1, 2027; (ii) 25% on March 1, 2028; (iii) 25% on March 1, 2029 and (iv) the remaining 25% on March 1, 2030, so long as the Reporting Person remains an employee or other service provider of the Issuer through such date. Represents shares automatically sold by the Company on behalf of the reporting person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations. The sale does not represent a discretionary trade by the reporting person. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.17 to $11.91, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.22 to $12.095, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 25% of the option shares shall vest and become exercisable on March 1, 2027, with the remaining 75% vesting in thirty-six (36) equal monthly installments thereafter, such that the option shares will be fully vested on March 1, 2030.
